Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66(5): 839-51.
Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis 2014; 20(1): 196-212.
Alves A, Panis Y, Bouhnik Y, et al. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn’s disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007; 50(3): 331-6.
Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg 2008; 12(10): 1738-44.
Bafford AC, Powers S, Ha C, et al. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn’s disease. J Clin Gastroenterol 2013; 47(6): 491-5.
Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohn’s Colitis 2013; 7(11): 853-67.
Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis 2012; 6(3): 281-6.
Brouquet A, Maggiori L, Zerbib P, et al. Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic crohn disease: results of a prospective nationwide cohort. Ann Surg 2018; 267(2): 221-8.
de Buck van Overstraeten A, Eshuis EJ, Vermeire S, et al. Short- and medium-term outcomes following primary ileocaecal resection for Crohn’s disease in two specialist centres. Br J Surg 2017; 104(12): 1713-22.
Eshuis EJ, Al Saady RL, Stokkers PC, et al. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohn’s Colitis 2013; 7(2): 142-9.
Fumery M, Seksik P, Auzolle C, et al. Postoperative complications after ileocecal resection in crohn’s disease: a prospective study from the remind group. Am J Gastroenterol 2017; 112(2): 337-45.
Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn’s disease patients. World J Surg 2009; 33(5): 1049-52.
Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18(12): 2404-13.
Morar PS, Hodgkinson JD, Thalayasingam S, et al. Determining predictors for intra-abdominal septic complications following ileocolonic resection for crohn’s disease-considerations in pre-operative and peri-operative optimisation techniques to improve outcome. J Crohn’s Colitis 2015; 9(6): 483-91.
Rizzo G, Armuzzi A, Pugliese D, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis 2011; 26(11): 1435-44.
Lightner AL, Raffals LE, Mathis KL, et al. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohn’s Colitis 2017; 11(2): 185-90.
Lightner AL, Mathis KL, Tse CS, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: Retrospective multicenter cohort study. Inflamm Bowel Dis 2018; 24: 871-6.
Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol 2017; 112(9): 1423-9.
Koh S, Zaghiyan K, Fleshner P. Safety and efficacy of the perioperative use of vedolizumab in medically refractory IBD patients. Does "gut-specificity" impact surgical morbidity? American
Society of Cataract and Refractive Surgery/American Society of
Ophthalmic Administrators (ASCRS/ASOA) annual meeting; April 30-May 4, 2016. Los Angeles, CA
Schils N, De Buck van Overstraeten A, Vermeire S, et al. Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn’s disease undergoing right hemicolectomy with ileocolonic anastomosis. 12th Congress of European Crohn’s and Colitis Organizationi (ECCO). February 15-18, 2017; Barcelona, Spain.
Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in vedolizumab-treated Crohn’s disease patients undergoing major abdominal operations. Aliment Pharmacol Ther 2018; 47: 573-80.
Ferrante M, de Buck van Overstraeten A, Schils N, et al. Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohn’s Colitis 2017; 11(11): 1353-61.
Lightner AL, McKenna NP, Moncrief S, et al. Surgical outcomes in vedolizumab-treated patients with ulcerative colitis. Inflamm Bowel Dis 2017; 23(12): 2197-201.
Kiely JM, Fazio VW, Remzi FH, Shen B, Kiran RP. Pelvic sepsis after IPAA adversely affects function of the pouch and quality of life. Dis Colon Rectum 2012; 55(4): 387-92.
Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol 2017; 15(10) 1580-8 e3
Ungar B, Levy I, Yavne Y, et al. Optimizing anti-tnf-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2016; 14(4) 550-7 e2.
Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 16(5): 697-705. e7
Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther 2018; 47(7): 906-12.
Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 16(12): 1937-46. e8
Al Bawardy B, Piovezani Ramos G, Willrich MAV, et al. Clinical experience with vedolizumab trough levels in inflammatory bowel disease. Gastroenterol 2018; 154(6): S821-22.
Rosario M, Wyant T, Leach T, et al. Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers. Clin Drug Investig 2016; 36(11): 913-23.
Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015; 261(3): 487-96.
Zimmerman LA, Zalieckas JM, Shamberger RC, Bousvaros A. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg 2018; 53(7): 1330-3.
Lightner AL, Tse CS, Potter DD Jr, Moir C. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. J Pediatr Surg 2018; 53(9): 1706-9.
Schleier L, Wiendl M, Binder M-T, et al. α4ß7 integrin-dependent
gut homing of non-classical monocytes is essential for intestinal
wound healing mediated by M2 mamcrophages. 13th Congress of
european crohn's and colitis organization Vienna, Austria. 2018 14-7.